Weight-loss drugs like Ozempic may be doing more than trimming waistlines. Early research shows they could also curb cravings for alcohol, opioids and nicotine.

Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, were originally developed to treat diabetes and obesity. Now, scientists are discovering just how useful these drugs might be in treating other conditions.

Researchers found that drugs such as Ozempic or Wegovy act on the brain’s reward circuits, helping reduce the drive for addictive substances, according to a recent study.

Early trials show promising results in treating addiction. In people with alcohol use disorder, low-dose semaglutide reduced alcohol consumption, drinks per drinking day and cravings. Rodent studies suggest similar benefits for opioid and nicotine use, lowering self-administration and relapse-like behaviors.

The overlap between the pathways that control appetite and those involved in addiction may explain why a medication designed to curb hunger could also reduce substance-seeking behavior. Researchers caution that current findings are preliminary, but they could indicate a new era in addiction therapy.

With substance use disorders affecting millions worldwide, yet fewer than one in four people receiving treatment, drugs like Ozempic may offer hope where current options are limited, researchers said. Scientists emphasize more research is needed, but the potential to treat obesity, diabetes and addiction simultaneously promotes optimism for the future.

Who knew your weight-loss medications might also be helping your brain fight unhealthy cravings?